Results 51 to 60 of about 15,255 (159)

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)

Cancer Innovation, Volume 5, Issue 3, June 2026.
This consensus, based on the latest evidence‐based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice. ABSTRACT Breast cancer represents a major threat to women's health in China.
Fei Ma, Binghe Xu, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center   +5 more
wiley   +1 more source

Vinorelbine as a radiosensitizer in Pakistani patients with locally advanced unresectable head & neck cancer (HNC) in tertiary care hospital of Pakistan

International Journal of Endorsing Health Science Research, 2019
Background: Head and neck cancer (HNC) is one of the most common cancers in Pakistan. Disease free survival in HNC remains poor due to inefficient loco-regional disease control. The aim of the present study was to assess the response rate and toxicity of
Rana Atique Anwer Khan, Ahmed Ijaz Masood, Sadaqat Ali Gorchani, Muhammad Junaid, Ali Yasir Khan   +4 more
doaj   +1 more source

Metastatic Ewing Sarcoma, Patterns of Care and Outcomes of Patients in a Real‐Life National Setting Over a Decade

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Metastatic Ewing sarcoma (MES) has a poor prognosis. This multicenter observational study provides real‐world data on treatment patterns of patients with MES in France. Treatment characteristics, outcomes such as time to next treatment (TTNT) and overall survival (OS), and prognostic factors of patients aged ≥ 12 years treated for a MES in 11 ...
Coline Ducrot, Derek Dinart, Maeva Bonneau, Max Piffoux, Marie Sophie Minot, Juliane Mignot‐Posson, Thomas Grinda, Jordane Chaix, Sarah Winter, Pauline Gerard, Romain Duong, Berengère Narciso, Natacha Entze Werle, Cécile Vérité, Valérie Laurence, Axel Le Cesne, Pablo Berlanga, Camille Tlemsani, Pascaline Boudou‐Rouquette, Emmanuelle Bompas, Thibaud Valentin, Nadège Corradini, Mehdi Brahmi, Carine Bellera, Maud Toulmonde   +24 more
wiley   +1 more source

Vinca Alkaloids

International Journal of Preventive Medicine, 2013
Vinca alkaloids are a subset of drugs obtained from the Madagascar periwinkle plant. They are naturally extracted from the pink periwinkle plant, Catharanthus roseus G. Don and have a hypoglycemic as well as cytotoxic effects.
Maryam Moudi, Rusea Go, Christina Yong Seok Yien, Mohd Nazre   +3 more
doaj  

Characteristics and Outcomes of Patients With Dedifferentiated Liposarcoma in a US Community Setting

Cancer Medicine, Volume 15, Issue 6, June 2026.
US community oncology patients with dedifferentiated liposarcoma have heterogeneous profiles, treatments, and outcomes. The poor survival rates in this population suggest an unmet need for better therapeutics. ABSTRACT Introduction Clinical characteristics and outcomes of patients treated for dedifferentiated liposarcoma (DDLPS) at community oncology ...
James E. Butrynski, Bal Nepal, Chenxiao Hu, Jinhong Guo, Jennifer Han, Lisa Herms, Alyssa B. Klein, Stephen Stanhope, Elizabeth L. Stanley, Karen Todoroff, Paul Conkling   +10 more
wiley   +1 more source

Vinorelbine causes a neuropathic pain-like state in mice via STING and MNK1 signaling associated with type I interferon induction

iScience
Summary: Type I interferons (IFNs) increase the excitability of dorsal root ganglia (DRGs) neurons via MNK-eIF4E signaling to promote pain sensitization in mice.
Úrzula Franco-Enzástiga, Keerthana Natarajan, Eric T. David, Krish Patel, Abhira Ravirala, Theodore J. Price   +5 more
doaj   +1 more source

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source

Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC [Corrigendum]

International Journal of Nanomedicine, 2021
Kong L, Zhang S, Chu J, et al. Int J Nanomedicine. 2020;15:6451–6468. The authors have advised due to an error at the time of figure assembly, Figure 6A on page 6463 is incorrect. The correct Figure 6 is shown in Download Article.
Kong L, Zhang S, Chu J, Liu X, Zhang L, He S, Yang S, Ju R, Li X   +8 more
doaj  

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Hodgkin lymphoma (HL) is a B‐cell‐derived malignancy often affecting young adults. Allocation into risk groups is based on staging with positron emission tomography and computed tomography (PET/CT) and the presence or absence of risk factors.
Dennis A. Eichenauer, Marc André, Peter Borchmann, Graham P. Collins, Ian Doherty, Hans‐Theodor Eich, Massimo Federico, Alexander Fossa, Sylvia Hartmann, Martin Hutchings, Timothy Illidge, Carsten Kobe, Wouter J. Plattel, Lena Specht, Anna Sureda, Jan M. Zaucha, Joseé M. Zijlstra, Igor Aurer   +17 more
wiley   +1 more source

Clinical Factors Associated With Non‐Completion of Durvalumab Maintenance Therapy After Chemoradiotherapy in Patients With Locally Advanced Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study

Thoracic Cancer, Volume 17, Issue 12, June 2026.
Among 80 patients with locally advanced NSCLC receiving durvalumab after CCRT, 44 patients (55%) did not complete 12 months of treatment. Lower A/G ratio and higher RDW‐SD before durvalumab initiation may serve as exploratory signals for non‐completion, closer monitoring, and supportive care planning.
Masaaki Kotake, Satoshi Watanabe, Yuki Sakai, Toshiaki Kikuchi, Akira Toyama   +4 more
wiley   +1 more source